Activating enhancer-binding protein 2a (AP-2a) and activating enhancer-binding protein 2c (AP-2c) are transcription factors that bind GC-rich consensus sequences and regulate the expression of many downstream genes. AP-2a and AP-2c interact with p53 both physically and functionally. Expression microarray results in human breast carcinoma cells with forced p53 expression revealed AP-2c as a putative transcriptional target of p53. To confirm and extend these findings we measured the effects of forced p53 expression in human breast carcinoma cells by real-time reverse transcription-PCR, Western blotting, electrophoretic gel mobility shift assays, promoter reporter, chromatin immunoprecipitation and chromatin accessibility assays. Wild-type p53 expression rapidly induced not only AP-2c but also AP-2a mRNA. The subsequent increase in these proteins led to increased AP-2 DNAbinding and transactivating activity. Candidate p53-binding sites were identified in the AP-2a and AP-2c promoters. p53 binding to these cis-elements in vivo was also observed, together with a relaxation of chromatin structure in these regions. Finally, expression of either AP-2a or c inhibited growth of human breast carcinoma cells in vitro. Taken together, our findings indicate that these AP-2 genes are targets for transcriptional activation by p53 and suggest that AP-2 proteins may mediate some of the downstream effects of p53 expression such as inhibition of proliferation.
Introduction
The family of activating enhancer-binding protein 2 (AP-2) transcription factors consists of five different genes known as AP-2a, AP-2b, AP-2g, AP-2d and the recently discovered AP-2e, respectively (Williams et al., 1988; Hilger-Eversheim et al., 2000; Zhao et al., 2001; Tummala et al., 2003) . The AP-2 monomer has a multidomain structure consisting in the order from N-to C-terminus of a less-conserved proline-rich transactivation domain, a highly conserved basic helical DNAbinding domain and dimerization domain unique to this family (Hilger-Eversheim et al., 2000) . AP-2a is a retinoic acid-inducible and developmentally regulated transcription activator. Both AP-2a and AP-2g are required in early embryonic development (Schorle et al., 1996; Zhang et al., 1996; Hilger-Eversheim et al., 2000) . AP-2 exists in both homo and heterodimeric forms. The AP-2 dimer can interact with many proteins to control the expression of many genes.
AP-2-regulated genes include c-Kit, which regulates cellular proliferation and differentiation ; MUC18 (melanoma-associated glycoprotein), an adhesion molecule involved in angiogenesis ; MMP-2 (matrix metalloproteinase-2), which is involved in invasion (Bar-Eli, 2001 ); and KAI1 (prostate cancer antimetastasis gene 1), a prostate-specific metastasis suppressor (Marreiros et al., 2003) . When AP-2 is lost, less c-Kit and KAI1, but more MUC18 and MMP2, are produced, resulting in a cell's increased potential to grow and divide uncontrollably Jean et al., 1998; Bar-Eli, 2001; Marreiros et al., 2003) . It has been reported that AP-2a overexpression can reduce thymidine incorporation and 5-bromo-2 0 -deoxyuridine incorporation, which are indicators of DNA synthesis (Wajapeyee and Somasundaram, 2003) . Both phosphorylated Rb and the universal cell cycle inhibitor p21 WAF1/CIP1 have been reported to be induced by AP-2a overexpression (Zeng et al., 1997; Wajapeyee and Somasundaram, 2003) . In addition to arresting cell cycle progression, AP-2 was found to induce apoptosis as demonstrated by cleaved PARP (poly ADP-ribose polymerase product) and decreased DNA content (Hilger-Eversheim et al., 2000; Wajapeyee and Somasundaram, 2003) . The retinoblastoma-related Rb2/p130 gene was also found to be a downstream effector of AP-2 in neural differentiation (Paggi et al., 2001; West-Mays et al., 2003) . Taken together, these findings provide evidence that AP-2 participates in complex developmental dynamics including blocking cell cycle progression, promoting apoptosis and inducing differentiation.
Various studies have shown that AP-2 has tumor suppressor activity in breast cancer cells, melanoma cells and prostate cancer cells. Low nuclear AP-2 expression in human breast cancer was found to be associated with disease progression and increased metastatic capability of the tumor (Pellikainen et al., 2002) . Additionally, reduced nuclear AP-2 expression independently predicted elevated risk of recurrent disease in breast (Gee et al., 2000) . Moreover, the loss of AP-2 expression seems to be associated with malignant transformation and tumor progression in malignant melanoma Gee et al., 2000; Bar-Eli, 2001; Tellez et al., 2003) . Decreased AP-2 expression is associated with elevated risk of subsequent metastatic behavior in stage I cutaneous malignant melanoma (Karjalainen et al., 1998; Karjalainen et al., 2000) . Re-expression of AP-2 in the highly metastatic melanoma cells decreased their tumorigenicity and inhibited their metastatic potential in nude mice (Bar-Eli, 2001 ). It has been demonstrated that a loss of AP-2a expression occurs early in the development of prostate adenocarcinoma (Ruiz et al., 2001) and AP-2a is a target of DNA methylation-mediated silencing in human breast cancer cells (Douglas et al., 2004) .
p53 is a well-known tumor suppressor involved in diverse cellular processes, including cell cycle regulation, apoptosis, senescence, DNA repair, cell differentiation and angiogenesis (Vogelstein et al., 2000) . It is reported that there is a physical and functional interaction between p53 and AP-2 proteins (McPherson et al., 2002; Modugno et al., 2002) . The presence of p53 and p21 can enhance AP-2a-induced cell cycle arrest and AP-2a-decreased DNA synthesis (McPherson et al., 2002; Wajapeyee and Somasundaram, 2003) . Both the p53 and AP-2 transcription factors can upregulate p21, arrest cell cycle progression, induce apoptosis and promote tumor death. It has been suggested that tumor suppressor activity of AP-2 is closely related to wild-type (wt) p53 expression. Thus, we performed experiments to determine whether AP-2 transcription factors are targets for transcriptional activation by p53.
Our data identified AP-2a and AP-2g as wt p53 target genes. We used Ad-p53 (wt)-eGFP (green fluorescent protein) to elevate wt p53 expression and measured the effects of forced p53 expression in breast carcinoma cells by microarray analysis, real-time reverse transcription (RT)-PCR, Western blotting, electrophoretic gel mobility shift assays and promoter reporter assays. Our results indicated that wt p53 overexpression induces AP-2a and AP-2g mRNA and protein accumulation. We used an AP-2 responsive chloramphenicol acetyltransferase (CAT) reporter assay to analyse AP-2 transactivating activities and radiolabeled AP-2 consensus binding sites to determine the AP-2 DNAbinding ability after Ad-p53 infection. Both the reporter activity and DNA-binding ability increased in Ad-p53-infected MDA MB-231 cells. Furthermore, chromatin immunoprecipitation assay and chromatin accessibility assay were used to demonstrate the accumulation of p53 on AP-2 promoters in vivo and the opening of local chromatin structure. Thus, AP-2 transcription factors are targets for transcriptional activation by p53.
Results
Multi-dimensional scaling analysis of results from the microarray expression studies in human breast-derived cells with forced p53 expression revealed that eight of 11 human breast cell lines displayed a specific pattern of gene expression (Oshiro et al., 2003) . Among the genes upregulated by p53 was AP-2g. Table 1 shows that AP-2g mRNA was consistently increased as a result of wt p53 overexpression in eight human breast-derived cell lines. Although the fold increase varied among the cell lines, it was clear that AP-2g mRNA was consistently increased by wt p53 expression. Among the eight cell lines, MDA MB-231 and BT-549 were chosen for future studies of AP-2 as they were p53 responsive and represented cells that bracketed the mean AP-2g response. Both these human breast carcinoma cell lines have a mutant p53 gene. MDA MB-231 has undetectable levels of AP-2a and a low but detectable level of AP-2g as determined by Western blotting. BT-549 cells constitutively express AP-2a and AP-2g at a basal level. To independently validate whether p53 overexpression could induce AP-2 accumulation, we used an adenoviral vector that coexpressed wt p53 and eGFP as a fluorescence marker to monitor infection efficiency. An empty vector that expresses eGFP only, Ad-Bgl II (eGFP), was used to control for the specific effects of p53. To test whether the AP-2 induction requires the p53 DNAbinding activity, we included the Ad-mt p53 described in the Materials and methods in following experiments. Twenty-four hours after adenoviral infection, nuclear proteins were isolated from the cells for analysis. The at an MOI of 100. Twenty-four hours after infection, total RNA was isolated from each cell population, and microarray analyses were performed on a 5K array as described in Materials and methods. Data from Ad-p53-infected cells were normalized to non-infected cells or virus controlinfected cells as indicated. The average and median fold increases of AP-2g mRNA compared to uninfected (left column) or Ad-BglIIinfected cells (right column) were calculated.
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H Li et al levels of p53 protein were detected by Western blot and, as seen in Figure 1a ( (Figure 1a, insert) . The same phenomenon was demonstrated in BT-549 cells (Supplementary Figure 8 ). To determine whether the p53 expressed by Ad-p53 was fully functional, we confirmed the induction of p21 mRNA and increased p53 DNAbinding ability in the Ad-p53-infected cells (data not shown).
To confirm and extend the microarray results, that overexpression of wt p53 leads to upregulation of AP-2g mRNA, we studied MDA MB-231 cells and BT-549 cells that had been infected with Ad-p53 (wt), Ad-Bgl II (eGFP) or Ad-p53 (R175H) at various multiplicities of infection (MOI). We found that not only the level of AP-2g mRNA but also AP-2a mRNA was increased by overexpressing wt p53 in a dose-dependent manner in both MDA MB-231 and BT-549 cells (Figure 1a and b) . However, in untreated cells, or cells treated with Ad-Bgl II (eGFP) or Ad-p53 (R175H), AP-2a and AP2g mRNA levels were not induced (Figure 1a and b) . In MDA MB-231 cells, there was no additional increase in AP-2 levels at 150 MOI Ad-p53-infected cells compared to 100 MOI Ad-p53-infected cells. This might be owing to the toxicity of wt p53 expression or to toxicity of the high titer of adenovirus. Nevertheless, these results confirm the microarray expression studies and extend them to demonstrate that not only AP-2g but also AP-2a mRNA levels are significantly increased by wt p53 overexpression. The finding that p53 (R175H) was unable to cause upregulation of AP-2 transcription factors suggests that activation of their expression appears to require wt p53 DNA-binding ability.
As AP-2a and AP-2g mRNA levels had been increased by overexpressing p53, we further studied whether this resulted in increased AP-2 proteins. Therefore, the protein levels of AP-2a and AP-2g were examined by Western blotting after overexpressing wt p53 in both cell lines. We found that both AP-2a and AP-2g protein levels (Figure 2a and b) were increased by overexpressing wt p53 in a dose-dependent manner. In noninfected, Ad-Bgl II (eGFP)-infected and Ad-p53 (R175H)-infected cells, AP-2a and AP-2g protein levels remained at low levels (Figure 2a and b) . These results demonstrated that AP-2a and AP-2g protein levels increased in agreement with mRNA levels.
Having confirmed by real-time RT-PCR and Western blot analysis that p53 upregulated AP-2a and AP-2g, we examined the kinetics of induction and found that AP-2a and AP-2g mRNA began to increase at B24 and B12 h following Ad-p53 infection in MDA MB-231 and BT-549 cells, respectively, and that the mRNA levels continued to increase until 30 h post-infection, the last time point examined (Supplementary Figure 7) . We also wished to determine the temporal relationship between acquisition of p53 and AP-2 expression at the protein level in these breast cancer cells. We found that p53 Figure 8) . Thus, p53 protein levels accumulated earlier than AP-2 proteins in both cell lines, consistent with a causal role for p53 in the upregulation of AP-2. The different rates of AP-2 responses to p53 in these two cell lines suggest that they have different adenovirus infection efficiencies and/or protein-expressing machinery. Indeed, it is highly possible that p53-induced AP-2 expression displays cell type specificity.
In order to detect the transactivating activity of p53-induced AP-2 protein, 12 Â AP-2 responsive CAT reporter assay, which has 12 AP-2 consensus binding sites at the enhancer region of CAT reporter gene (Figure 3a) , was carried out. Ad-AP-2-infected cells showed the expected increases in the respective AP-2 proteins ( Figure 3b ). Having established the system, we tested the 12 Â AP-2 CAT reporter in response to AP-2a and AP-2g forced expression. AP-2a and AP-2g overexpression significantly increased CAT activity ( Figure 3c ). Interestingly, we found AP-2g had an apparently higher potential to drive the 12 Â AP-2 CAT reporter than AP-2a at comparable MOIs. Moreover, the combination of AP-2a and AP-2g gave even higher CAT activity compared with AP-2a or AP-2g alone (Figure 3c , last lane). We found that overexpression of wt p53 significantly increased AP-2-mediated transactivation in a dose-dependent manner, whereas CAT activity remained at relatively low levels in adenovirus control-and plasmid control-treated MDA MB-231 cells ( Figure 3d ). In addition, the low levels of CAT activity in vector control-infected and Ad-mt p53-infected cells indicated the failure to elevate not only AP-2 responsive reporter activity but also AP-2 protein induction by Ad-mt p53 as shown previously in Figure 2 . As wt p53 can induce both AP-2a and AP-2g, it has good potential to drive AP-2 responsive reporter activity.
AP-2 DNA-binding activity is vital for its function. Therefore, we began to determine whether there was increased AP-2 DNA-binding ability resulting from the induction by p53 in BT-549 cells. We found that AP-2 DNA-binding activity was increased in Ad-p53-infected BT-549 cells (Figure 3e ). The specificity of AP-2 DNA binding was assessed using AP-2a-and AP-2g-specific antibodies. Addition of AP-2g-specific antibody showed a better AP-2 supershift compared to AP-2a. We interpret this to mean that the fraction of AP-2g is higher in BT-549 cells, which is consistent with the relatively higher levels of AP-2g mRNA and protein in Ad-p53-infected cells, as shown in Supplementary Figure 8C . Moreover, other AP-2 family members may account for part of AP-2-binding activity as neither antibody provided a complete supershift. Owing to the low level of AP-2 protein in MDA MB-231 cells, AP-2 DNA-binding activity induced by p53 was difficult to detect by EMSA in these cells.
Two potential mechanisms could account for the AP-2 mRNA accumulation in response to p53. One is increased mRNA stability and the other is elevated transcriptional activity. To determine which mechanism was more prominent in this system, we used actinomycin-D, a well-known transcription blocker to stop AP-2 transcription and measure AP-2a and AP-2g mRNA half-lives. Our results indicated that neither the half-life of AP-2a mRNA nor AP-2g mRNA was increased in response to p53-mediated upregulation (Supplementary Figure 9) . Thus, we reasoned that elevated transcriptional activation accounts for the increase in the steady-state levels of AP-2a and AP-2g mRNA and began to investigate this possibility.
A search of 2 kb of the 5 0 ends of the AP-2a and AP2g genes using Transmission Element Search Software (Petsko, 2002) revealed two potential p53-binding sites (AP-2a proximal and distal) in the AP-2a 5 0 end and one potential p53-binding site (AP-2g distal) in the AP-2g 5 0 end (Supplementary Figure 10A) . We designed flanking real-time RT-PCR primers according to these putative p53-binding sites, as well as a gel shift probe. Chromatin immunoprecipitation (ChIP) assays were used to determine whether detectable p53 was bound to the corresponding p53 putative binding sites in cellular nuclei. Of the eight breast carcinoma cell lines initially screened by microarray analysis, four cell lines were chosen and ChIPed using p53 antibody. Real-time PCR analyses of the purified ChIPed DNA showed that p53 antibody pulled down significantly more p53-bound AP-2a promoter DNA in three of four Ad-p53-infected cell lines compared with vector control-infected cell lines (Figure 4) . Thus, p53 accumulation on p53 cognate binding sites in vivo might also require specified chromatin modifications, structural alterations, post-translational modifications or the presence additional cofactors. It is known that p53 not only binds to its regulatory binding sites to upregulate target genes but also induces opening of chromatin structure and facilitates recruiting the transcriptional machinery (Watts et al., 2004) . Thus, to determine the chromatin accessibility in regulatory regions corresponding to the putative p53-binding sites, we designed and utilized three pairs of primers that amplify the three p53 candidate binding sites. As the AP-2a proximal putative p53-binding site is near the transcription initiation site, it is predicted that this region of chromatin is open and accessible to transcriptional machinery when the transcriptional activity is elevated. Therefore, we designed another pair of primers located just before the AP-2a transcription initiation site aimed at determining the accessibility of this region to basal transcriptional factors. In the chromatin accessibility assay, the more open the chromatin is, the more accessible it is to DNase. The more DNase digestion of the target sequence, the less PCR products will be generated and the real-time PCR amplification plot will be shifted to the right. As shown in Figure 5a Total proteins from adherent cells were collected 30 h after infection. These proteins were used to measure CAT activity in the lysates, indicative of the level of AP-2 transactivating potential. b-Gal assays were performed on the same lysates and used to normalize between samples to adjust for differences in transfection efficiencies. *Po0.05 compared with control. wPo0.05 compared with AP-2a and AP-2g combination treated cells (lane 7). (e) Electrophoretic gel mobility shift assays were carried out to detect AP-2 DNA-binding activity in different adenovirus-infected BT-549 cells using a radiolabeled AP-2 consensus binding site as a probe. Nuclear proteins were collected 30 h after 100 MOI infection. Specificity was determined by using different AP-2 antibodies in supershift reactions. (Figures 4 and 5) indicate that p53 not only binds to the AP-2 promoters but also modifies their chromatin structure to facilitate AP-2 transcription. A proposed model for these phenomena is presented in Figure 6 .
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In order to determine whether both AP-2a and AP-2g mediate the impact of p53 on cell growth behavior, we measured the total cell number (adherent and floating cells) after infection with AP-2-expressing adenovirus. We found that AP-2 induction can significantly reduce MDA MB-231 cell growth in a manner similar to that of p53 (Supplementary Figure 11) .
Discussion
There are many proteins and redundant pathways to protect cells from tumor formation. Besides p53, Rb, p16 and others, AP-2a and AP-2g are also implicated in tumor suppression (Zeng et al., 1997) . AP-2a and AP-2g, two members of the AP-2 family, are transcription factors with high homology to each other. It has been reported that there is a physical interaction between p53 and AP-2 proteins (McPherson et al., 2002; Modugno et al., 2002) . Most importantly, the functional interaction between these two proteins was discovered and it was demonstrated that both the p53 and AP-2 transcription factors can upregulate p21, arrest cell cycle progression, induce apoptosis and promote tumor death (McPherson et al., 2002; Wajapeyee and Somasundaram, 2003) . Therefore, it has been suggested that the tumor suppressor activity of AP-2 is closely related to wt p53 expression. It was recently reported that TAp63a, a newly discovered member of the p53 family that binds to similar DNA-binding sequences, can induce AP-2g during mouse epidermal morphogenesis (Koster et al., 2006) . These results are in total agreement with our findings and suggest that the p53 family might regulate the function and expression of AP-2 family members during different stages of normal development or disease processes. In this study, we have identified genes encoding AP-2 transcription factors as targets for transcriptional activation by overexpression of p53. It should be noted that overexpression of p53 may not be equivalent to endogenous p53 expression levels, but overexpression systems have served as models for subsequent identification of true physiological interactions. In addition, the levels of wt p53 expression achieved by adenovirus infection in this study are not dissimilar to those in cells exposed to genotoxic stress. Therefore, it is possible that these AP-2 proteins may mediate some of the downstream effects of p53 expression that occur as a result of such stress. We demonstrated that p53 overexpression could upregulate AP-2a and AP-2g mRNA and protein levels. The induced AP-2 was competent at high-affinity DNA binding both in vitro and in vivo. As a DNA-bindingdefective mutant failed to elicit a comparable effect, p53 DNA-binding ability was essential to exhibit the characteristics of tumor-suppressing function described herein. Even though the presence of p53 can improve AP-2-induced cell killing, AP-2 alone can greatly induce breast carcinoma cell death (McPherson et al., 2002; Wajapeyee and Somasundaram, 2003) . Indeed, the fact that AP-2 expression decreased MDA MB-231 cell growth (Supplementary Figure 11) implies that AP-2 may mediate part of p53 function in growth inhibition. Thus, it would be desirable to develop therapeutic strategies aimed at breast cancer that were based on targeted disruption or overexpression of AP-2 either independent of p53 or in combination with p53.
In the current study, the mechanisms involved in p53-induced AP-2 accumulation were investigated. We first ruled out the possibility of increased AP-2 mRNA stability after p53 expression by measuring the AP-2 AP-2 regulation by p53 H Li et al mRNA half-life. We found that both AP-2a and AP-2g mRNA half-lives were shortened after Ad-p53 infection compared to vector control (Supplementary Figure  9) . It was interesting to note that overexpression of AP-2a can significantly reduce p53 expression and that decreased AP-2 expression results in increased p53 protein (Stabach et al., 2005) . Taken together our current findings suggest that there is a feedback loop between AP-2 and p53. When AP-2 is weakly expressed, the system increases p53. In contrast, when AP-2 is normal or induced, p53 is repressed and AP-2 half-life is shortened. This is physiologically significant for the cell and organism to control transcription factors to their required levels. After confirming that there was not any increase in AP-2 mRNA stability upon p53 overexpression, we identified two p53-binding sites on AP-2a and one on the AP-2g 5 0 -flanking region up to 2 kb from the major transcription initiation sites. Chromatin immunoprecipitation assays showed that p53 binds to AP-2a and AP2g promoters in vivo and leads to chromatin remodeling and an increase in chromatin accessibility within the transcriptional regulatory regions of these two genes. Therefore, p53 appears to open the chromatin flanking this region to enhance its own function and/or recruit transcriptional factors to the specific region. In this way, the p53 downstream target genes will be modulated efficiently and extensively. Among the four cell lines examined, only MDA MB-231, which has the lowest endogenous and p53-inducible AP-2 expression, displayed minimal p53 enrichment on the AP-2 promoter. This might be because the association of p53 with the AP-2 promoter is below the limit of detection in this cell line. However, we still cannot rule out additional mediators between p53 protein increase and AP-2 mRNA induction. Some of these mediators may be very important for p53-induced AP-2 expression and perhaps that is why this phenomenon is cell type specific. One of the most plausible candidates for such an additional mediator is reactive oxygen species (ROS), as p53 is known to induce ROS production and AP-2 was reported to be redox-regulated (Polyak et al., 1997; Huang and Domann, 1998) . It is also possible that other p53-induced proteins participate in AP-2 upregulation. According to our microarrary data, there are three of 11 breast carcinoma cell lines showing no changes of AP-2 level after Ad-p53 infection (data not shown). These data indicate that this is not a general effect of forced wt p53 expression, but rather has cell line-and likely cell type-specific character. 
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In contrast to the tumor suppressor effects of AP-2, it plays a very important and indispensable role in embryogenesis and development (Schorle et al., 1996; Zhang et al., 1996) . The AP-2 knockout mice have lethal defects and usually die at birth (Hilger-Eversheim et al., 2000) . However, the absence of p53 has no effect on mouse embryo development and only increases the tumorigenesis at later age (Donehower et al., 1992; Hursting et al., 1994) . This is in contrast to the absence of TAp63a in mice that show widespread loss of epithelial tissues where AP-2 is known to play an important role including skin and breast (Mills et al., 1999; Yang et al., 1999) . Taken together, these lines of evidence indicate that AP-2 and p53 family members have different functions at various developmental and lifetime periods. Therefore, alterations in the normal expression levels of these proteins during development and aging may participate in tumor formation.
Future work will seek to identify additional cofactors or mediators of AP-2 induction by p53 and further study how the interaction and association of AP-2 and p53 affects the individual functions of each protein. It would also be interesting to know what functions of p53 are mediated or at least partially mediated through upregulation of AP-2 transcription factors. Overall, this study identified AP-2a and AP-2g as p53 downstream target genes. Taken together, our results suggest that the interaction between AP-2 and p53 extends beyond a simple physical association to an apparently higher ordered functional interaction that involves chromatin structure and remodeling.
Materials and methods

Cell culture
Human breast adenocarcinoma MDA MB-231 cells and BT-549 cells were obtained from the American Type Culture Collection (Rockville, MD, USA). They were routinely cultured in RPMI 1640 medium and 10% fetal bovine serum supplemented with 50 mg/ml penicillin/streptomycin, and incubated at 371C with 95% air and 5% CO 2 . Medium was changed every 3-4 days. Cells were serum deprived overnight before they were infected or transfected and were maintained in serum-free media for the remainder of the experiment to inhibit serum stimulation of the AP-2 pathway. Cells were kept in full serum media when we confirmed that wt p53-expressing adenovirus could elevate p53 level and its corresponding biological function.
Adenovirus constructs AP-2a cDNA provided by Dr Trevor Williams (Williams et al., 1988) was subcloned into pcDNA3 mammalian expression vector (Invitrogen, Carlsbad, CA, USA). The AP-2g expression vector AP-2g-pcDNA3 was generously provided by Dr Ronald J Weigel (McPherson and Weigel, 1999) . Both Ad-AP-2a and Ad-AP-2g adenoviruses were manufactured at the University of Iowa's Gene Transfer Vector Core Facility. The corresponding vector control was Ad-Bgl II, which contains only the adenovirus backbone. Ad-p53 and Ad-p53 R175H (also called mt p53 in some figure legends), which express our gene of interest and eGFP, were generous gifts from Bert Vogelstein (Yu et al., 1999) . The Ad-p53 R175H (mt p53) is a point mutation from arginine to histidine at codon 175 that is commonly found in breast cancer and which abrogates p53 DNA-binding ability (Chen et al., 1993) . The control virus of Ad-p53 was Ad-Bgl II (eGFP), an empty virus backbone that expressed only eGFP. All adenovirus stocks were maintained at the University of Iowa's Vector Core Facility where infectious particles were also amplified, purified and characterized.
Plasmid constructs
An AP-2 responsive reporter construct, 12 Â AP-2-CAT, was used to characterize AP-2 transactivating activity in cells expressing p53. This construct contains 12 AP-2 consensus binding sites located upstream of the bacterial CAT gene and was made as described previously (Zhu et al., 2001) . The empty vector Basic-CAT (Promega, Madison, WI, USA) was used as vector control. CMV-b-galactosidase plasmid DNA (Promega) was co-transfected for normalization of transfection efficiency. (a) In the absence of wt p53, the promoter region of AP-2 is condensed and not accessible to the general transcriptional machinery. AP-2 expression remains low level. (b) After the transcriptional activator p53 binds to AP-2 promoter, it recruits transcriptional cofactors including p300 and others leading to chromatin remodeling and loosening the chromatin structure. (c) Owing to increasing accessibility to the transcriptional machinery, AP-2 has a greater expression in the presence of p53 than that in the absence of p53.
Transient transfection assays
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H Li et al b-Galactosidase activity in cell extracts was measured using 2-nitrophenyl-b-D-galactopyranoside (ONPG) (Sigma) as a colorimetric substrate. Thirty microgram samples of total cell proteins were added to 66 ml of ONPG solution (4 mg/ml, dissolved in 100 mM sodium phosphate, pH 7.5) and incubated at 371C until the solution became light yellow. Conversion of ONPG to galactose and o-nitrophenyl was determined spectrophotometrically at A 420 nm . CAT activity was normalized to b-galactosidase activity.
Microarray fabrication, multidimensional scaling and microarray data analysis Microarray hybridization and analysis was performed by the Arizona Cancer Center Genomics Shared Service as described previously (Oshiro et al., 2003) . Briefly, 11 human breast epithelial tumor cell lines were infected with 100 MOI of Ad-p53-eGFP or Ad-Bgl II (eGFP) or left untreated. Total RNA was isolated 24 h later, reverse transcribed, and labeled with Cy3 (eGFP) or Cy5 (p53-GFP). Labeled cDNAs were mixed and competitively hybridized to a 5760-gene (5k) cDNA microarray fabricated by the Genomics service. Raw data were normalized and 1118 genes were found to have data in 24 of 33 hybridizations and a Bonferroni-adjusted P-value less than 0.05 when treatment classes were compared. Multidimensional scaling based on the 1118 genes revealed that eight of 11 breast epithelial-derived cell lines exhibited a specific patterned response to forced p53 overexpression. Among the genes upregulated by p53 in human breast-derived cells was AP-2g. This preliminary observation led to the confirmation and extension of this finding in the present study.
Nuclear protein extraction Nuclear extracts were prepared according to the method of Dignam as described previously (Zhu et al., 2001) . Briefly, medium was removed from tissue culture dishes, cells were washed twice with phosphate-buffered saline (PBS) and scrape-harvested in 500 ml ice-cold hypotonic buffer (10 mM HEPES, 1.5 mM MgCl 2 , 10 mM KCl and 0.5 mM dithiothreitol (DTT)). Cells were incubated on ice for 20 min, then lysed by a glass dounce homogenizer with type B pestle and centrifuged at 300 g for 5 min. Supernatants were saved as cytosolic protein, and 40 ml ice-cold high salt buffer (20 mM HEPES, 25% glycerol, 0.42 M NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM PMSF and 0.5 mM DTT) was added to the nuclear pellets and mixed. The nuclei were incubated on ice for 15 min and centrifuged at the maximum speed for 1 min. Supernatants were saved as nuclear protein extract. Protein concentrations were determined with Bio-Rad DC protein assay (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer's instructions.
Western blotting
Various amounts of nuclear protein (50 mg for AP-2, 30 mg for p53 and 20 mg for actin) were size-fractionated on a 12% Tris-HCl polyacrylamide ready gel (Bio-Rad Laboratories). The separated proteins were then electro-transferred to a nitrocellulose membrane (Schleicher and Schuell, Keene, NH, USA) by running at 100 V for 1 h. For AP-2a and AP-2g Western blots, the primary antibodies were mouse anti-AP-2a IgG and mouse anti-AP-2g-IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA) respectively, both used at 1:400 dilution. For p53 Western blots, the primary antibody was mouse anti-p53 IgG (Oncogene Research Products, San Diego, CA, USA) used at 1:1000 dilution. For actin Western blots, the primary antibody was mouse anti-human b-actin (Santa Cruz Biotechnology) used at 1:2000 dilution. For AP-2, p53 and actin Western blots, the secondary antibody was goat antimouse IgG (Pharmingen, San Diego, CA, USA) used at 1:10 000 dilution. Blots were washed with TTBS (0.02 M trisHCl buffer pH 7.5, 0.137 M NaCl and 0.1% Tween 20). Detection by the chemiluminescence reaction was carried out using the enhanced chemiluminescence (ECL) kit (Amersham Pharmacia Biotech, Piscataway, NJ, USA), followed by exposure to Kodak X-ray film.
Electrophoretic gel mobility shift assays We used double-stranded oligodeoxynucleotides containing a consensus AP-2-binding sequence (Promega). The probe was made by labeling these double-stranded oligonucleotides with [g-32 P]ATP using T4 polynucleotide kinase. After this, 10 mg of nuclear protein was incubated with the 32 P-radiolabeled oligonucleotide probe in the presence of 1 mg of poly(dIdC) (Amersham Pharmacia Biotech) and 1 Â gel shift buffer (10 mM Tris, pH 7.5; 50 mM NaCl; 1 mM MgCl 2 ; 0.5 mM EDTA; 0.5 mM DTT; and 4% glycerol) at room temperature for 20 min. The binding reactions were loaded onto a 5% polyacrylamide gel and run at 100 V in 1 Â TBE (90 mM Tris, 90 mM boric acid, 2 mM EDTA, pH 8.0). The gels were wrapped in plastic wrap and exposed to X-ray film (Kodak) overnight at À801C. To assess the specificity of the binding reaction, antibodies specific to AP-2 were used in gel supershift assays to verify that the DNA-binding activity measured was due specifically to AP-2. For gel supershift, 1 ml of anti-AP-2 antibody (Santa Cruz Biotechnology) was incubated with each binding reaction for 20 min before loading onto the gel.
Real-time reverse transcription-PCR analysis
Total RNA was extracted using the Qiagen RNeasy kit (Qiagen Inc., Valencia, CA, USA). The reverse transcription step was performed using one-step RT-PCR TaqMan Master Mix Reagents (Roche Molecular Systems, Branchburg, NJ, USA). Reverse transcription was carried out at 481C for 30 min. The PCR conditions were 951C for 10 min, followed by 40 cycles of denaturation at 951C for 30 s, annealing and extension at 601C for 1.5 min. One-step RT-PCR was performed and the data collected using the ABI Prism 7000 real-time sequence detection system (Applied Biosystems). The gene-specific TaqMan probes were labeled with the 5 0 reporter dye, 6-FAM, and a 3 0 end that contains a non-fluorescent quencher and a minor groove binder. Differences in expression were determined using relative quantity calculated by standard curve. All genes of interest were normalized to b-actin as a reference mRNA. AP-2a and b-actin primers and probe were purchased from assays on demand of Applied Biosystems (Assay IDs of AP-2a and b-actin are Hs00231461_m1 and Hs99999903_m1, respectively). AP-2g primers and probe were purchased from assays by design of Applied Biosystems (AP-2g forward primer sequence: TGACCAAGAACCCTC TGAACCT, reverse primer sequence: CCAGGGACTGAGC AGAAGAC and probe sequence: CCCACCAGCTCCTTCT). p21 mRNA level was determined by SYBR Green master mix (Applied Biosystems )using forward primer: ATCCCGTGTT CTCCTTT and reverse primer: GCTGGCATGAAGCC.
Chromatin immunoprecipitation assays
The p53 chromatin immunoprecipitations were carried out according to the methods described previously (Oshiro et al., 2003) . Cells were treated with 1% formaldehyde for 10 min. The cells were then gently scraped and collected by centrifugation at 41C. Cell pellets were resuspended in PIPES buffer (5 mM PIPES pH 8.0, 85 mM KCl, 0.5% NP-40) and incubated on ice for 10 min, then resuspended in SDS lysis buffer. DNA-protein complexes were sonicated to lengths between AP-2 regulation by p53 H Li et al 200 and 1000 bp as determined by gel electrophoresis. Samples were centrifuged at 16 000 g at 41C to spin out cell debris, and then the supernatant was diluted 10-fold with ChIPs dilution buffer. One-tenth of the sample was set aside for input control, and the remaining sample was precleared with protein A/G PLUS Agarose (Santa Cruz Biotech). Following the preclearing step, the sample was split in half and one portion was incubated with 30 ml of anti-p53 antibody conjugated to agarose beads (clone DO1, Oncogene Research Products) or 30 ml of protein A/G PLUS agarose. Following an overnight incubation at 41C, the beads were washed with low-salt, highsalt and LiCL wash buffers, then twice with Tris-EDTA pH 8.0. The chromatin-antibody complexes were eluted and the DNA-protein crosslinks were reversed with 0.4 M NaCl (final concentration) at 651C for 4 h. Samples were subsequently treated with proteinase K, and genomic DNA was recovered by phenol/chloroform extraction and quantitated using a BioPhotometer (Eppendorf Scientific, Hamburg, Germany).
Quantitative real-time PCR was used to analyse ChIP DNA using the Applied Biosystem Inc. Prism 7000 sequence detector following ABI's SYBR s Green PCR Master Mix protocol. Real-time PCR was carried out in triplicate on 5 ng of ChIP DNA using the universal conditions outlined by the ABI user manual. The corresponding PCR primers used wereas follows: AP-2a proximal forward primer: TTATCAGTTCGCAGGCT GGA, AP-2a proximal reverse primer: GCTCGCCAGTACC ACAATCTG; AP-2a distal forward primer: GGAAATATGG GAGGCCTGGA, AP-2a distal reverse primer: GTTACCTC TGTCTTTTCTCTCTGCTATATGT; AP-2g distal forward primer: GAGCACCTTCTTGCCCATTC, AP-2g distal reverse primer: TCTCTGACCCGGCCTGAG. Quantitation of PCR products was determined by applying the comparative threshold cycle number (C t ) method, as described in the ABI 7000 user guide and by Litt et al., (2001) and Oshiro et al. (2003) . The fold enrichment of p53 occupancy on the AP-2 promoters was determined by the following equation: Chromatin accessibility assay BT-549 cells were infected with Ad-Bgl II (eGFP) or Ad-p53 of 100 MOI. After 24 h infection, cells were washed twice with and scraped in 1 Â PBS. The cells were pelleted by centrifugation and resuspended in 1 Â RBS (10 mM Tris ph 7.5, 10 mM NaCl, 3 mM MgCl 2 and 0.5% NP-40). After incubation for 5 min on ice, Trypan blue staining was carried out to make sure cells were completely broken. RNase A in 1 Â SuRE/Cut buffer H for restriction enzymes (Roche) was added after spin at 300 g for 1 min. Nuclei were counted after spin and resuspending in 1 Â restriction buffer. Aliquots of five million nuclei each were brought up to 200 ml 1 Â SuRE/Cut buffer H for restriction Enzymes. One aliquot from each treatment was set as control. Twenty units of RQ1 Dnase (Promega) was used to digest DNA at 371C. After 10 min digestion, 10 ml of 0.5 M EDTA was added to stop the reaction and 10 ml of 20 mg/ml proteinase K (Qiagen) was used to digest the protein at 371C. The remaining DNA was sonicated using a Vibra cell sonicator (Sonics and Materials Inc., Newton, CT, USA) at 50% power for 20 s to improve the isolation efficiency in the subsequent step. DNA was then isolated using DNeasy kit (Qiagen) according to the manufacturer's protocol, quantified using a Biophotometer (Eppendorf) and diluted to same concentration. Four nanograms of DNA was mixed with SYBR Green PCR master mix (Eurogentech, San Diego, CA, USA) to run real-time PCR using ABI Prism 7000 sequence detection system (Applied Biosystems). The following real-time PCR primers were used: AP-2a 0-500 forward primer: GCTCACC GCCGGCA, AP-2a 0-500 reverse primer: GGATCGGCGTG AACGG; the other primers were the same as those used for the ChIP assays described above. Chromatin accessibility indices were calculated according to the equation index ¼ 2 ðC t cutÀCt uncutÞ (C t : threshold cycle number).
